scholarly journals Carvedilol seems no better than metoprolol for heart failure

BMJ ◽  
1999 ◽  
Vol 318 (7197) ◽  
pp. 1509-1509
Author(s):  
S. Gottlieb
Keyword(s):  
Heart Failure ◽  
Better Than

scholarly journals Continuous infusion or bolus injection of loop diuretics for patients admitted for severe acute heart failure: Is one strategy better than the other?

2015 ◽  
Vol 34 (2) ◽  
pp. 95-102 ◽  
Author(s):  
Francisca Caetano ◽  
Paula Mota ◽  
Inês Almeida ◽  
Andreia Fernandes ◽  
Ana Botelho ◽  
...  
Keyword(s):  
Heart Failure ◽  
Continuous Infusion ◽  
Acute Heart Failure ◽  
Bolus Injection ◽  
Loop Diuretics ◽  
The Other ◽  
Better Than

Is dynamic desaturation better than a static index to quantify the mortality risk in heart failure patients with Cheyne-Stokes respiration?

2018 ◽  
Vol 28 (10) ◽  
pp. 106312 ◽  
Author(s):  
Philine Granitza ◽  
Jan F. Kraemer ◽  
Christoph Schoebel ◽  
Thomas Penzel ◽  
Jürgen Kurths ◽  
...  
Keyword(s):  
Heart Failure ◽  
Mortality Risk ◽  
Heart Failure Patients ◽  
Better Than

Is isosorbide mononitrate better than the dinitrate?

1984 ◽  
Vol 22 (2) ◽  
pp. 7-8
Keyword(s):  
Heart Failure ◽  
Heart Disease ◽  
Ischaemic Heart Disease ◽  
Isosorbide Dinitrate ◽  
Slow Release ◽  
Haemodynamic Effects ◽  
Isosorbide Mononitrate ◽  
Better Than

Similar oral preparations of isosorbide mononitrate have recently been marketed by four unrelated companies. This is unusual but understandable for an unpatentable drug of promise. Like other nitrates this drug has anti-anginal and haemodynamic effects of value in the treatment of ischaemic heart disease and heart failure. The manufacturers claim that its 100% bioavailability should make it more effective, longer acting and more acceptable than slow-release isosorbide dinitrate (ISDN).

scholarly journals Not all cardiac glycosides are equal: Could ouabain prove to be better than digoxin for heart failure?

2015 ◽  
Vol 24 ◽  
pp. S213
Author(s):  
A. Garcia ◽  
C. Liu ◽  
W. Hannam ◽  
N. Fry ◽  
H. Rasmussen
Keyword(s):  
Heart Failure ◽  
Cardiac Glycosides ◽  
Better Than

Different expression of adrenoceptors and GRKs in the human myocardium depends on heart failure ethiology and correlates to clinical variables

2012 ◽  
Vol 303 (3) ◽  
pp. H368-H376 ◽  
Author(s):  
Fermí Montó ◽  
Eduardo Oliver ◽  
Diana Vicente ◽  
Joaquín Rueda ◽  
Jaime Agüero ◽  
...  
Keyword(s):  
Heart Failure ◽  
Protective Role ◽  
Left Ventricular ◽  
Left Ventricular Ejection ◽  
Compensatory Mechanisms ◽  
Human Heart Failure ◽  
Ventricular Ejection Fraction ◽  
Clinical Variables ◽  
G Protein Coupled ◽  
Better Than

Downregulation of β1- adrenergic receptors (β1-ARs) and increased expression/function of G-protein-coupled receptor kinase 2 (GRK2) have been observed in human heart failure, but changes in expression of other ARs and GRKs have not been established. Another unresolved question is the incidence of these compensatory mechanisms depending on heart failure etiology and treatment. To analyze these questions, we quantified the mRNA/protein expressions of six ARs (α1A, α1B, α1D, β1, β2, and β3) and three GRKs (GRK2, GRK3, and GRK5) in left (LV) and right ventricle (RV) from four donors, 10 patients with ischemic cardiomyopathy (IC), 14 patients with dilated cardiomyopathy (DC), and 10 patients with nonischemic, nondilated cardiopathies (NINDC). We correlated the changes in the expressions of ARs and GRKs with clinical variables such as left ventricular ejection fraction (LVEF) and left ventricular end-systolic and left ventricular end-diastolic diameter (LVESD and LVEDD, respectively). The main findings were 1) the expression of the α1A-AR in the LV positively correlates with LVEF; 2) the expression of GRK3 and GRK5 inversely correlates with LVESD and LVEDD, supporting previous observations about a protective role for both kinases in failing hearts; and 3) β1-AR expression is downregulated in the LV and RV of IC, in the LV of DC, and in the RV of NINDC. This difference, better than an increased expression of GRK2 (not observed in IC), determines the lower LVEF in IC and DC vs. NINDC.

Home telemonitoring for congestive heart failure: a systematic review and meta-analysis

2009 ◽  
Vol 16 (2) ◽  
pp. 68-76 ◽  
Author(s):  
Julie Polisena ◽  
Khai Tran ◽  
Karen Cimon ◽  
Brian Hutton ◽  
Sarah McGill ◽  
...  
Keyword(s):  
Heart Failure ◽  
Systematic Review ◽  
Congestive Heart Failure ◽  
Usual Care ◽  
Meta Analysis ◽  
Clinical Effectiveness ◽  
Home Telemonitoring ◽  
Home Telehealth ◽  
Better Than

We conducted a systematic review of the literature about home telemonitoring compared with usual care. An electronic literature search was conducted to identify studies of home telemonitoring use in congestive heart failure (CHF) patients. Twenty-one original studies on home telemonitoring for patients with CHF were included (3082 patients). A random effects model was used to compute treatment efficacy to measure the average effect of the intervention across all studies where the quantitative pooling of results was appropriate. Home telemonitoring reduced mortality (risk ratio = 0.64; 95% CI: 0.48–0.85) compared with usual care. Several studies suggested that home telemonitoring also helped to lower the number of hospitalizations and the use of other health services. Patient quality of life and satisfaction with home telemonitoring were similar or better than with usual care. More studies of higher methodological quality are required to give more precise information about the potential clinical effectiveness of home telehealth interventions.

scholarly journals 570 Myocardial deformation imaging after STEMI: can we better predict one-year mortality and heart failure development?

2020 ◽  
Vol 21 (Supplement_1) ◽  
Author(s):  
D Trifunovic ◽  
G Krljanac ◽  
M Asanin ◽  
L Savic-Spasic ◽  
S Aleksandric ◽  
...  
Keyword(s):  
Heart Failure ◽  
Total Mortality ◽  
Wall Layer ◽  
Clinical Parameters ◽  
Deformation Imaging ◽  
Atrial Contraction ◽  
Endocardial Layer ◽  
One Year ◽  
Conventional Echocardiography ◽  
Better Than

Abstract Prognosis after STEMI is still challenging. One-year mortality ranges between 10-12% and the incidence of heart failure (HF) is between 4% and 28%. Early and accurate identification of high-risk patients necessitates therapy intensification. Aim this study is a part of PREDICT-VT study (NCT03263949). The aim was to test whether deformation imaging based on spackle tracking echocardiography predict MACE (total mortality, HF hospitalization and NYHA class ≥3 development) better than conventional echocardiography and clinical parameters. Methods in 264 consecutive pts enrolled in PREDICT-VT study early echocardiography (5 ± 2 days after pPCI) was done including LA and multilayer LV deformation analysis with longitudinal (L), radial (R) and circumferential (C) strain (S; %) and strain rate (SR, 1/sec). LV index of post systolic shortening for longitudinal (PSS LS) and circumferential (PSS CS) strain were calculated as average of PSS over 18 LV segments. Results 198 patients completed 1-year follow-up and 22 patients (11.1%) experienced MACE. Significant echo, clinical and laboratory predictors with the ROC analysis are listed in the table according to AUC . Conclusion peak systolic longitudinal and to a lesser degree peak systolic circumferential deformation predict mortality and HF development after pPCI better than conventional echo and even clinical parameters. From diastolic parameters only radial SR during atrial contraction was better MACE predictor compared to conventional echocardiography. AUC p Cut-off Senz Spec Peak systolic LS epicardial layer 0.757 <0.001 -11 75 63 Radial SR during atrial contraction 0.754 <0.001 -0.63 65 80 Peak systolic LS mid-wall layer 0.750 <0.001 -12.58 80 60 PSS LS endocardial layer 0.744 <0.001 0.1409 70 61 Peak systolic CS endocardial layer 0.744 <0.001 -18.08 70 67 Wall Motion Score Index 0.740 0.001 1.53 70 70 Peak systolic CS mid-wall layer 0.730 0.001 -13.66 80 60 Peak radial LV strain 0.722 0.001 14.08 80 60 Creatine kinase peak level 0.698 0.003 2155 64 73 LV EF 0.692 0.004 47.5 67 60 TAPSE 0.685 0.015 1.95 75 60 LA strain 0.676 0.012 18.33 63 64 Killip class 0.644 0.028

Sign in / Sign up

Export Citation Format

Share Document